A GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management.
The effect of glucagon-like peptide 1 receptor agonists (GLP-1RAs) on systolic blood pressure (SBP) in patients with obesity with or without diabetes remains unclear. The aim was to compare the effect of different drug-dose combinations of GLP-1RAs o…
INTRODUCTION: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are increasingly prescribed for glycemic control and weight loss, but their effects on surgical outcomes remain incompletely understood. Delayed gastric emptying and associated perio…
BACKGROUND: Coronary artery disease is the leading cause of death worldwide. It imposes an enormous symptomatic burden on patients, leaving many with residual disease despite optimal procedural therapy and up to one-thirds with debilitating angina am…
Medical therapeutics for weight loss are changing the landscape of obesity but impacts on obesity-associated cancer remain unclear. We report that in pre-clinical models with significant retatrutide (RETA, LY3437943)-induced weight loss, pancreatic c…
IMPORTANCE: Obesity, a chronic disease with escalating global prevalence, poses considerable health risks. Glucagon-like peptide 1 receptor agonists (GLP-1RAs), including liraglutide, semaglutide, and tirzepatide, have demonstrated efficacy for weigh…
GLP-1 receptor agonists are known to produce weight loss in people with obesity. Whether either drug can prevent weight gain by nonobese individuals has received little research attention. The present studies investigated the ability of liraglutide a…
CagriSema is a combination of amylin (cagrilintide) and glucagon-like peptide-1 (semaglutide) analogues being developed for weight management. Here, we show that CagriSema blunts metabolic adaptation in rats. Quantifying CagriSema's action on energy…
BACKGROUND: Multiple meta-analyses (MAs) have demonstrated that six pharmacotherapies, including orlistat, liraglutide, phentermine/topiramate, naltrexone/bupropion, semaglutide, and tirzepatide, improve weight loss and weight maintenance. However, f…
PURPOSE: To compare the hazard of age-related macular degeneration (AMD) among nondiabetic, weight loss-eligible adults prescribed glucagon-like peptide-1 receptor agonists (GLP-1 RAs; semaglutide or liraglutide) versus other weight loss (OWL) pharma…
BACKGROUND: Pharmacologic therapies for heart failure with preserved ejection fraction (HFpEF) have shown limited efficacy, and the impact of GLP-1 receptor agonists (GLP-1 RAs) remains unclear. This meta-analysis evaluates their effects on mortality…
Introduction This study aims to evaluate the risk of residual gastric content (RGC) among patients taking semaglutide/tirzepatide undergoing an esophagogastroduodenoscopy (EGD). Methods A retrospective observational study was conducted from 2024 to 2…
BACKGROUND: Type 2 diabetes mellitus (T2DM), one of the most common chronic metabolic diseases, is also one of the most significant risk factors for cardiovascular disease (CVD) and chronic kidney disease (CKD). AIM: To conduct a systematic review an…
A recent article highlighted the hepatic benefits of intermittent fasting, particularly during Ramadan. However, the rising use of glucagon-like peptide-1 (GLP-1)/glucose-dependent insulinotropic polypeptide (GIP) receptor agonists (RAs) is altering…
PURPOSE: Obesity remains a significant public health issue in the Western world, affecting millions of Americans and contributing to chronic conditions such as diabetes and hypertension. In June 2021, the Food and Drug Administration approved semaglu…
In the management of hypertension, only limited advances have been made over the past decades. Recent studies highlight the potential of next-generation incretin-based therapeutics, such as GLP-1 RAs (glucagon-like peptide-1 receptor agonists) like s…
Obesity affects over 1 billion people worldwide and is linked to more than 230 health complications, with cardiovascular disease being a leading cause of mortality. Losing 5%-10% of body weight is considered clinically significant for improving healt…
OBJECTIVES: In this study, the comparative bioavailability of semaglutide following the administration of oral (PO) and subcutaneous (SC) doses in healthy subjects was evaluated. The pharmacokinetics of semaglutide of these formulations at lower dose…
BACKGROUND: Aboriginal and Torres Strait Islander Australians experience worse healthcare outcomes due to increased prevalence of cardiovascular disease (CVD). A large proportion of this is preventable if CVD risk factors, such as obesity, are effect…